Biotechnology Right To Health In Russia.

1. Introduction

The Right to Health in Russia is a constitutional and statutory right that protects individuals' access to medical treatment, healthcare services, medicines, preventive healthcare, medical technologies and scientific advances in biotechnology.

Biotechnology has become increasingly important to the Russian healthcare system through developments in:

Genetic testing and genomic medicine.

Gene therapy and cell-based treatments.

Regenerative medicine and tissue engineering.

Biopharmaceuticals and genetically engineered medicines.

Vaccines and immunological products.

Assisted reproductive technologies.

Personalized medicine and molecular diagnostics.

Biomedical research and clinical trials.

Biotechnological treatments for rare and hereditary diseases.

The relationship between biotechnology and the right to health raises an important legal question: To what extent must the Russian State ensure that scientific and biotechnological advances are safe, accessible, affordable and consistent with human dignity?

Russian law recognizes healthcare as a constitutional responsibility of the State. However, the right to health does not automatically create an unlimited right to every experimental, newly developed or expensive biotechnology treatment. Access is governed by constitutional guarantees, healthcare legislation, medicines regulation, medical-product authorization and public funding arrangements.

2. Constitutional Framework: Article 41 of the Russian Constitution

The principal constitutional foundation is Article 41 of the Constitution of the Russian Federation.

It establishes three important guarantees.

A. Right to health protection and medical assistance

Article 41(1) recognizes everyone's right to health protection and medical assistance. Medical assistance in state and municipal healthcare institutions is provided free of charge through public budgets, insurance contributions and other resources.

This provision creates a constitutional foundation for:

Publicly funded medical treatment.

Access to essential medicines.

Preventive and diagnostic services.

Healthcare for people with disabilities.

Medical research and development.

Safe application of advanced medical technologies.

B. State responsibility for healthcare development

Article 41(2) requires federal programmes for the protection and improvement of public health to be financed by the State. It also supports the development of state, municipal and private healthcare services.

In biotechnology, this responsibility is relevant to government support for:

Research into hereditary diseases.

Development of vaccines.

Production of biological medicines.

Genetic diagnostic infrastructure.

Regenerative medicine.

Advanced treatments for rare diseases.

C. Protection against concealment of health risks

Article 41(3) provides that officials who conceal facts or circumstances threatening human life and health may be held responsible under federal law.

This provision has particular importance in biotechnology because concealment of clinical-trial risks, contaminated biological products, defective vaccines or adverse effects of experimental treatments can threaten public health.

The constitutional protection is reinforced by Articles 2, 7, 17, 19, 20, 21 and 46, concerning human dignity, the social character of the State, equality, life, personal dignity and judicial protection.

WIPO+1

 

3. Federal Law No. 323-FZ of 21 November 2011

The principal legislation governing the right to health is Federal Law No. 323-FZ, On the Fundamentals of Health Protection of Citizens in the Russian Federation.

This legislation establishes the legal, organizational and economic framework of healthcare and determines the rights and responsibilities of patients, healthcare institutions and public authorities.

Its relevance to biotechnology can be understood through the following provisions.

A. Article 4 – Basic principles of health protection

The legislation recognizes principles including:

Observance of citizens' rights in healthcare.

Priority of patients' interests.

Priority of children's health protection.

Social protection of citizens.

Responsibility of public authorities and healthcare organizations.

Availability and quality of medical assistance.

These principles require biotechnology-based healthcare to be administered in a manner consistent with patient protection and public-health objectives.

B. Article 10 – Availability and quality of medical assistance

The law establishes the principle of availability and quality of medical assistance.

This is relevant when patients require advanced diagnostic procedures, biological medicines, genetic testing or specialized treatment.

For example, if a patient with a rare genetic disorder requires a medically indicated treatment, the healthcare system must apply the relevant statutory eligibility and funding rules rather than arbitrarily discriminate against the patient.

C. Articles 19 and 20 – Patient rights and informed consent

Article 19 recognizes the right to medical assistance and other healthcare rights.

Article 20 establishes informed voluntary consent as a fundamental requirement for medical intervention, subject to legally specified exceptions.

In biotechnology, informed consent is particularly important for:

Genetic testing.

Experimental treatments.

Cell-based therapies.

Clinical trials.

Collection of biological samples.

Medical interventions involving advanced technologies.

Patients must receive relevant information about the proposed intervention, its purpose, methods, risks and possible consequences.

D. Article 22 – Information about health

Patients have rights concerning information about their health, including access to relevant medical information.

This is important when genetic testing identifies hereditary conditions or potentially serious biological risks.

Healthcare professionals must respect applicable confidentiality and medical-secrecy requirements.

E. Article 37 – Medical assistance according to established procedures

Medical assistance is organized and provided according to applicable procedures and standards.

Consequently, the use of biotechnology must comply with the relevant authorization, professional, clinical and safety requirements.

CIS Legislation+1

4. Federal Law No. 180-FZ of 23 June 2016: Biomedical Cell Products

One of the most important biotechnology-specific laws is Federal Law No. 180-FZ, On Biomedical Cell Products.

It regulates the development, preclinical research, clinical research, examination, registration, manufacture, quality control, distribution, application, storage, transportation and safety monitoring of biomedical cell products.

The legislation is particularly important for regenerative medicine and cell-based treatments.

Its principal areas include:

ProvisionLegal significance
Article 3Principles governing biomedical cell products
Articles 4–7Cell-line preparation, development and preclinical research
Articles 8–20Registration and expert examination
Article 14Ethical examination
Articles 28–30Clinical research
Article 31Rights of patients participating in clinical research
Article 32Mandatory insurance of clinical-trial patients
Articles 33–34Biological-material collection and donor rights
Article 39Medical assistance involving biomedical cell products
Articles 41–42Safety monitoring and suspension of use
Article 48Compensation for harm caused by biomedical cell products

Consultant Plus+1

Legal importance

The law creates a regulatory system intended to ensure that cell-based treatments are scientifically evaluated and subject to appropriate safety and quality controls.

For example, a biotechnology company developing a cell-based treatment cannot simply market it as a medical treatment without complying with the applicable registration and authorization requirements.

The law also protects individuals who participate in clinical research by recognizing specific patient rights and insurance protections.

Thus, the legislation connects the constitutional right to health with scientific accountability and patient safety.

5. Federal Law No. 61-FZ of 12 April 2010: Circulation of Medicines

Another important law is Federal Law No. 61-FZ, On the Circulation of Medicines.

It regulates the development, preclinical testing, clinical trials, registration, manufacturing, quality control, storage, transportation, importation, distribution and use of medicines.

This law has substantial importance for biotechnological medicines, including:

Recombinant proteins.

Monoclonal antibodies.

Biological vaccines.

Immunological preparations.

Biopharmaceutical products.

Certain gene- and cell-related medicinal technologies.

The regulatory framework aims to ensure that medicines meet applicable standards of quality, efficacy and safety.

The Federal Service for Surveillance in Healthcare (Roszdravnadzor) supervises important aspects of medicine circulation, including safety monitoring, quality control and preferential medicine provision.

roszdravnadzor.gov.ru+1

 

Relationship with the right to health

A medicine's scientific innovation does not automatically establish a patient's right to receive it free of charge.

The entitlement depends on the applicable healthcare programme, prescription, registration status, medical indication and statutory funding arrangements.

However, where a patient has an established legal entitlement to a medicine, failure to provide it may raise serious constitutional and legal questions.

6. Federal Law No. 86-FZ of 5 July 1996: Genetic Engineering Activities

The Federal Law on State Regulation in the Field of Genetic Engineering Activities is important for protecting human health against risks associated with genetic-engineering activities.

It addresses the relationship between genetic-engineering activities, environmental protection, ecological safety and human health.

The legislation also contains provisions concerning the legal basis for the transfer of human genetic data.

Its importance includes:

Protection against risks associated with genetically modified organisms.

Regulation of relevant genetic-engineering activities.

Protection of ecological and sanitary safety.

Recognition of legal issues involving genetic information.

Prevention of activities that may create risks to human health.

An important distinction is that the law does not itself comprehensively regulate every form of human gene therapy or genetic intervention. Its statutory scope must be distinguished from the regulation of medical interventions under healthcare legislation.

CIS Legislation

7. Biotechnology, Genetic Privacy and the Right to Health

Genetic information can reveal sensitive information about an individual's health, hereditary conditions and potential disease susceptibility.

Therefore, the right to health must be considered alongside the protection of personal information.

Relevant legislation includes:

Federal Law No. 152-FZ of 27 July 2006 on Personal Data.

Federal Law No. 323-FZ on the Fundamentals of Health Protection.

Federal Law No. 86-FZ on Genetic Engineering Activities.

Genetic testing may reveal information about family members as well as the individual being tested.

For example, a genetic test identifying a hereditary cancer predisposition may create questions concerning:

Patient confidentiality.

Disclosure to relatives.

Medical consent.

Storage of genetic information.

Unauthorized commercial use.

Discrimination in healthcare and other settings.

The right to health should therefore not be interpreted as permission for unrestricted collection or distribution of genetic information.

8. Important Case Laws Concerning the Right to Health in Russia

Russian biotechnology law is still developing, and there is no extensive body of reported court decisions specifically dealing with gene therapy, genome editing or biomedical cell products. Nevertheless, constitutional and human-rights decisions concerning access to medicines, discrimination, medical treatment and public-health protection establish important principles applicable to biotechnology.

Case 1. Constitutional Court of Russia – Judgment No. 4-P of 12 March 2015 (HIV-positive foreign nationals)

Important Russian constitutional precedent

Facts:

The case concerned HIV-positive foreign nationals who had family relationships in Russia. Russian authorities had applied immigration provisions that permitted refusal of residence or deportation because of HIV status.

The applicants challenged the legality of applying these provisions without considering their family circumstances, medical condition and humanitarian considerations.

Legal issue:

Whether the automatic application of HIV-related immigration restrictions was consistent with constitutional equality, family protection and human dignity.

Decision:

The Constitutional Court held that the relevant statutory provisions were unconstitutional insofar as they permitted immigration restrictions solely because an individual was HIV-positive, without considering relevant individual circumstances.

The Court emphasized that authorities must consider:

The person's family situation.

The person's health condition.

The clinical stage of the disease.

Compliance with public-health requirements.

Other exceptional humanitarian circumstances.

Biotechnology and right-to-health significance:

This judgment establishes an important principle: a person's biological or medical condition cannot automatically justify discriminatory treatment.

It is relevant to genetic testing, hereditary diseases, infectious-disease screening and personalized medicine.

For example, an individual with a genetic predisposition to a disease should not automatically be treated as an immediate public-health threat.

Consultant Plus+1

Case 2. Kiyutin v. Russia (2011), Application No. 2700/10

European human-rights precedent

Court: European Court of Human Rights.

Facts:

Mr Kiyutin, an Uzbek national, applied for a Russian residence permit. His application was rejected because he was HIV-positive.

He argued that the refusal interfered with his family life and discriminated against him on the basis of his health status.

Legal issue:

Whether refusing residence to an HIV-positive individual without an adequate individualized assessment violated the European Convention on Human Rights.

Decision:

The European Court found a violation of Article 14, taken together with Article 8 of the European Convention.

The Court recognized that people living with HIV constituted a particularly vulnerable group and that their exclusion required convincing justification.

Legal principle:

Health-related differences in treatment require objective and reasonable justification. Generalized assumptions about disease transmission cannot replace evidence-based individual assessment.

Biotechnology significance:

The judgment is relevant to:

Genetic and genomic discrimination.

HIV and other infectious-disease testing.

Health-status-based exclusion.

Medical screening.

Equal access to healthcare and related services.

It supports the principle that scientific and medical information must not become an instrument of unjustified discrimination.

ECHR+1

Case 3. Novruk and Others v. Russia (2016), Applications Nos. 31039/11 and Others

Court: European Court of Human Rights.

Facts:

Five HIV-positive foreign nationals were refused residence permits in Russia because of their HIV status.

The applicants argued that the immigration restrictions discriminated against them and interfered with their private and family lives.

Legal issue:

Whether the blanket application of HIV-related immigration restrictions was proportionate and compatible with the Convention.

Decision:

The European Court found a violation of Article 14 in conjunction with Article 8.

It emphasized that the Russian authorities had relied on generalized assumptions about HIV transmission rather than individualized assessments.

Legal principle:

Public-health protection is a legitimate governmental objective, but restrictions must be proportionate and supported by appropriate evidence.

Biotechnology significance:

This case is important for the regulation of predictive medical technologies.

For example, genetic screening results should not be used to impose blanket restrictions on individuals without a scientifically justified and legally appropriate basis.

ECHR+1

Case 4. Fedulov v. Russia (2019), Application No. 53068/08

Important access-to-medicines precedent

Court: European Court of Human Rights, judgment of 8 October 2019.

Facts:

Mr Fedulov suffered from advanced metastatic prostate cancer.

Under Russian social-assistance legislation, he was entitled to receive prescribed medicines free of charge. However, the designated pharmacy repeatedly failed to provide the required medicine, Bicalutamide, because of shortages.

He had to purchase the medicine himself and subsequently sought reimbursement.

Legal issue:

Whether the failure to provide medicines to which the applicant was legally entitled interfered with his protected property interests.

Decision:

The European Court recognized that the applicant had a sufficiently established entitlement under domestic law, amounting to a legitimate expectation protected by Article 1 of Protocol No. 1 to the Convention.

The failure to supply the medicine interfered with that protected interest.

Legal principle:

Where domestic legislation establishes an entitlement to a social or medical benefit, public authorities cannot disregard that entitlement without lawful justification.

Biotechnology significance:

This judgment is particularly relevant to patients who depend on expensive biotechnological medicines, including:

Cancer-related biological medicines.

Recombinant therapeutic proteins.

Rare-disease medicines.

Advanced immunological treatments.

It supports the principle that legally established access to medicines must be effectively implemented, not merely promised in legislation.

HUDOC+2

Case 5. Constitutional Court of Russia – Judgment No. 41-P of 26 September 2024

Recent and highly relevant precedent

Subject: Access to medicines for patients suffering from rare and life-threatening diseases.

Facts and legal background:

The case concerned the constitutionality of provisions of Federal Law No. 323-FZ relating to the responsibilities of regional authorities for providing medicines to patients suffering from rare diseases.

The relevant provisions were Article 16(1)(10) and Article 83(9).

The legal problem involved the absence of an adequate alternative mechanism when a regional authority could not properly fulfil its obligation to provide necessary medicines.

Legal issue:

Whether the State could leave patients suffering from serious rare diseases without medicines when the responsible regional authority failed to fulfil its statutory obligations.

Decision:

The Constitutional Court held that the relevant provisions were unconstitutional insofar as they failed to provide a reserve mechanism for supplying medicines to patients with qualifying rare diseases when the regional funding obligation could not be properly fulfilled.

The Court emphasized that:

Health is a constitutionally protected and inalienable human benefit.

The State must take sufficient and effective measures to protect life and health.

Public authorities must respect constitutional equality.

Financial and administrative limitations cannot justify the complete absence of an effective protection mechanism.

Biotechnology significance:

This judgment is especially important for biotechnology because rare diseases frequently require specialized and expensive treatments.

Examples include:

Genetic enzyme deficiencies.

Hereditary metabolic disorders.

Rare immunological conditions.

Certain genetic neurological diseases.

Diseases requiring specialized biological medicines.

The judgment strengthens the argument that the State must develop effective mechanisms for access to legally covered treatments.

However, it does not establish an unconditional right to every experimental or unregistered biotechnology product.

Consultant Plus+1

9. Application of the Right to Health to Specific Biotechnology Areas

A. Gene therapy and genome editing

Gene therapy creates possibilities for treating diseases by modifying or replacing genetic material.

Its legal implications include:

Protection of patient dignity.

Informed consent.

Scientific and clinical validation.

Monitoring of adverse effects.

Protection against unauthorized experimentation.

Appropriate regulatory authorization.

The constitutional right to health supports access to safe and legally authorized medical treatment, but it does not automatically authorize unrestricted human genome editing.

B. Regenerative medicine and stem-cell therapy

Regenerative medicine uses biological materials, cells and tissue-related technologies to repair or replace damaged biological structures.

Federal Law No. 180-FZ provides a specific framework for biomedical cell products.

Legal protection requires appropriate product registration, clinical research, quality controls, ethical examination and safety monitoring.

Unapproved cell-based treatments can expose patients to serious medical risks.

C. Biotechnological medicines for rare diseases

Rare-disease patients may require highly specialized medicines that are expensive or difficult to obtain.

The 2024 Constitutional Court Judgment No. 41-P is particularly important because it addresses the problem of gaps in public funding and medicine provision.

It demonstrates that constitutional protection of health requires an effective delivery mechanism.

D. Vaccines and immunological biotechnology

Vaccines are important biotechnology-based public-health products.

Their regulation involves:

Clinical research.

Registration.

Quality control.

Safety monitoring.

Adverse-event reporting.

Public-health administration.

The State must balance disease prevention with patient autonomy, medical safety and lawful public-health measures.

E. Genetic diagnostics and personalized medicine

Genetic diagnostic technologies can identify hereditary diseases and individual treatment responses.

Their application raises questions about:

Informed consent.

Accuracy of testing.

Confidentiality.

Genetic-data security.

Medical interpretation.

Prevention of discriminatory practices.

A genetic diagnosis should be handled as sensitive medical information, with appropriate legal safeguards.

10. State Institutions Responsible for Biotechnology and Healthcare Protection

Several public institutions have important responsibilities in this area.

InstitutionPrincipal responsibility
Ministry of HealthNational healthcare policy and medical regulation
RoszdravnadzorHealthcare supervision and medicine safety
RospotrebnadzorSanitary and epidemiological protection
Federal Medical-Biological Agency (FMBA)Specialized medical and biomedical activities
Federal Compulsory Medical Insurance FundCompulsory medical insurance system
Constitutional CourtConstitutional interpretation and protection of constitutional rights
Ordinary courtsJudicial remedies for healthcare and patient-rights disputes

The Ministry of Health plays a central role in the regulation of biomedical cell products, while Roszdravnadzor performs important supervision functions.

16reg.roszdravnadzor.ru+1

 

11. Legal Challenges in Protecting the Right to Health Through Biotechnology

Despite constitutional guarantees and statutory protections, Russia faces several legal and institutional challenges.

1. Unequal access to advanced treatment

Advanced biotechnology treatments may be concentrated in major medical institutions. Patients living in remote regions may experience difficulties accessing specialized genetic diagnostics, cell therapies and biological medicines.

2. High cost of biotechnology medicines

Some biological medicines and rare-disease treatments are extremely expensive. Regional differences in healthcare budgets can create difficulties in ensuring continuous access.

3. Experimental treatment risks

Patients suffering from incurable diseases may seek experimental biotechnology treatments. However, the desire to obtain treatment cannot eliminate the need for ethical review, informed consent and clinical safety requirements.

4. Genetic discrimination

Genetic information may be misused by employers, insurers or other organizations. Effective privacy protection and appropriate limits on the use of genetic information are essential.

5. Regulatory gaps

Emerging technologies such as CRISPR-based therapies, synthetic biology, artificial intelligence-assisted genomic medicine and advanced tissue engineering create regulatory challenges.

6. Scientific accountability

Healthcare institutions and biotechnology companies must maintain appropriate standards of scientific evidence, manufacturing quality, clinical monitoring and patient safety.

12. Remedies and Legal Accountability

Individuals whose right to health has been violated may have several legal remedies under Russian law.

These include:

Administrative complaints: Complaints to relevant healthcare authorities and supervisory institutions.

Judicial proceedings: Challenging unlawful decisions or failures by public authorities and healthcare organizations.

Compensation claims: Seeking compensation for harm caused by unlawful medical conduct or defective medical products, where statutory requirements are satisfied.

Constitutional complaints: Seeking Constitutional Court review where the applicable statutory provisions raise a constitutional-rights issue and procedural requirements are met.

Patient-rights protection: Challenging violations involving informed consent, medical confidentiality and access to legally guaranteed medical assistance.

Federal Law No. 323-FZ and Federal Law No. 180-FZ provide important foundations for patient protection and accountability.

13. International Human Rights Framework

Russia's constitutional right to health also has an important international legal background.

Relevant instruments include:

International Covenant on Economic, Social and Cultural Rights, particularly Article 12.

Universal Declaration of Human Rights, Article 25.

Convention on the Rights of the Child, Article 24.

Convention on the Rights of Persons with Disabilities, Article 25.

European Convention on Human Rights, particularly Articles 2, 3, 8 and 14, where applicable.

An important qualification concerns the European Convention: Russia ceased to be a party on 16 September 2022. Earlier European Court of Human Rights judgments against Russia remain important historical legal authorities for the relevant period, but the Convention does not provide the same post-withdrawal jurisdiction for subsequent events.

ECHR+1

 

14. Critical Legal Analysis

The Russian biotechnology right-to-health framework can be evaluated through five major principles.

Legal principleApplication to biotechnology
Human dignityProtection against degrading or unethical medical experimentation
EqualityNon-discriminatory access to healthcare
Patient autonomyInformed consent and medical decision-making
Patient safetyClinical evaluation and biotechnology-product regulation
State responsibilityPublic financing and effective access to legally guaranteed treatment

The most important distinction is between the right to health and the right to a particular biotechnology treatment.

Article 41 of the Russian Constitution protects health and medical assistance. It does not guarantee that every new scientific treatment must immediately be funded or made available.

Nevertheless, once legislation establishes a specific entitlement to treatment or medicines, public authorities must implement that entitlement effectively.

The Constitutional Court's Judgment No. 41-P of 2024 is particularly significant because it recognizes that the State must provide an effective alternative mechanism when regional authorities cannot fulfil their obligations concerning medicines for qualifying rare diseases.

This principle is relevant to the future development of personalized medicine, gene therapy and advanced biological treatments.

15. Conclusion

The Biotechnology Right to Health in Russia is based primarily on Article 41 of the Russian Constitution, Federal Law No. 323-FZ of 2011, Federal Law No. 180-FZ of 2016 and Federal Law No. 61-FZ of 2010.

Together, these legal instruments establish a framework for protecting patients, regulating biomedical innovations, controlling biological medicines and ensuring access to healthcare.

The most significant judicial authorities include:

Constitutional Court Judgment No. 4-P (2015) – protection against discriminatory treatment based solely on HIV status.

Kiyutin v. Russia (2011) – protection against health-status discrimination.

Novruk and Others v. Russia (2016) – proportionality of public-health restrictions.

Fedulov v. Russia (2019) – protection of legally established entitlement to free medicines.

Constitutional Court Judgment No. 41-P (2024) – effective provision of medicines to patients with qualifying rare diseases.

Ultimately, the Russian legal framework recognizes that biotechnology should serve human health rather than undermine human dignity, equality, patient autonomy or medical safety.

The central legal principle is that scientific progress must be accompanied by effective patient protection, responsible government regulation and meaningful access to legally guaranteed healthcare.

16. Important Legislation and Case Law for Academic Research

Legal authorityYearImportance
Constitution of the Russian Federation, Article 411993Constitutional right to health
Federal Law No. 86-FZ1996Genetic engineering regulation
Federal Law No. 61-FZ2010Medicines regulation
Federal Law No. 323-FZ2011Fundamental healthcare rights
Constitutional Court Judgment No. 4-P2015HIV-related equality and health protection
Federal Law No. 180-FZ2016Biomedical cell products
Novruk and Others v. Russia2016Health discrimination
Fedulov v. Russia2019Access to free medicines
Constitutional Court Judgment No. 41-P2024Rare-disease medicine provision

Primary research sources

Federal Law No. 323-FZ – Healthcare Protection.

Federal Law No. 180-FZ – Biomedical Cell Products.

Federal Law No. 86-FZ – Genetic Engineering.

Constitutional Court Judgment No. 4-P of 2015.

Constitutional Court Judgment No. 41-P of 2024.

European Court judgment – Fedulov v. Russia.

Research note: For formal legal citation, consult the official Russian-language versions of legislation and judgments, including subsequent amendments. The cases discussed above establish broader healthcare and human-rights principles; they should not be misrepresented as direct judicial decisions on gene-editing or cell-therapy disputes.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT